IKT

2.23

5.69% 0.12

Pre-mercato: 2.13 -0.10 -4.48%

Inhibikase Therapeutics Inc (IKT)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.11

Aprire:

$2.11

Volume 24 ore:

1.07M

Relative Volume:

1.20

Capitalizzazione di mercato:

$350.18M

Reddito:

$79,600

Utile/perdita netta:

$-48.26M

Rapporto P/E:

-4.5307

EPS:

-0.4922

Flusso di cassa netto:

$-28.24M

1 W Prestazione:

+13.78%

1M Prestazione:

+21.86%

6M Prestazione:

+35.15%

1 anno Prestazione:

+21.20%

Intervallo 1D:

$2.10

$2.26

Intervallo di 1 settimana:

$1.93

$2.36

Portata 52W:

$1.33

$2.36

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Nome

Inhibikase Therapeutics Inc

Settore

Healthcare (1089)

Industria

Biotechnology (603)

Telefono

(302) 295-3800

Indirizzo

1000 N. WEST STREET, SUITE 1200, WILMINGTON

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, RVMD, ALNY

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IKT Inhibikase Therapeutics Inc	2.23	350.18M	79,600	-48.26M	-28.24M	-0.4922
VRTX Vertex Pharmaceuticals Inc	480.50	121.95B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.15	70.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.19	52.94B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	180.39	38.35B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	272.67	36.40B	4.29B	577.22M	641.34M	4.2086

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-04	Iniziato	Ladenburg Thalmann	Buy
2026-01-21	Iniziato	BofA Securities	Buy
2025-12-26	Iniziato	H.C. Wainwright	Buy
2025-12-11	Iniziato	Cantor Fitzgerald	Overweight
2025-02-12	Downgrade	H.C. Wainwright	Buy → Neutral

Inhibikase Therapeutics Inc Borsa (IKT) Ultime notizie

Jul 20, 2026

Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo

Jul 20, 2026

Frontier tech research, news & data - MLQ.ai

Jul 20, 2026

Jul 18, 2026

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget

Jul 18, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat

Jul 18, 2026

Jul 17, 2026

RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT) - Stock Titan

Jul 17, 2026

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase - Stock Titan

Jul 17, 2026

Jul 16, 2026

IKT Receives FDA Orphan Designation for Pulmonary Arterial Hyper - GuruFocus

Jul 16, 2026

Jul 15, 2026

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Sahm

Jul 15, 2026

Inhibikase raises $50M to fund PAH program - TipRanks

Jul 15, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages - MarketBeat

Jul 15, 2026

Jul 14, 2026

Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale - Moomoo

Jul 14, 2026

Inhibikase raises $50 million through stock sale to RA Capital - Investing.com

Jul 14, 2026

Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView

Jul 14, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat

Jul 14, 2026

Inhibikase raises $50 million through stock sale to RA Capital By Investing.com - Investing.com Canada

Jul 14, 2026

Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash - Stock Titan

Jul 14, 2026

Inhibikase's $50M share sale could support Phase 3 PAH readout - Stock Titan

Jul 14, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9%Here's What Happened - MarketBeat

Jul 14, 2026

Jul 10, 2026

Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn ContinuesAnnual Earnings Summary - dars.gov.et

Jul 10, 2026

Jul 07, 2026